title: Inhibition of cancer cell proliferation by 5-fluoro-2'-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway.
abstract: Multiple epigenetic changes, including alterations in DNA methylation occur during tumorigenesis. Various inhibitors of DNA methylation have been developed to prevent proliferation of cancer cells. 5-fluoro-2(')-deoxycytidine (FCdR) is one such DNA methylation inhibitor, which is currently in phase II clinical trial. To investigate the molecular mechanism/s by which FCdR might mediate repression of tumor cell proliferation, we analyzed the toxicity of FCdR in various cell lines established from different sarcomas. We found HCT116, a colon cancer cell line, is much more sensitive to FCdR compared to others. FCdR treatment inhibited HCT116 cells at G2/M check point and up-regulated expression of multiple cancer-related genes, which could be due to its inhibitory activity towards DNA methylation. Furthermore, we found that FCdR activates DNA damage response pathway. Using an inhibitor for ATM and ATR kinases activity, which are required for amplifying the DNA damage repair signal, we show that FCdR induced inhibition of HCT116 cells at G2/M is mediated through activation of DNA damage response pathway.
  
  
  BACKGROUND
  The online version of this article (doi:10.1186/2193-1801-1-65) contains supplementary material, which is available to authorized users.
authors: Hubei Clinical Centre & Key Laboratory of Intestinal and Colorectal Diseases, and College of Life Sciences, Wuhan University, Wuhan, Hubei, 430072 China.
authors: Quanyi
authors: Q
authors: Zhao
authors: Jiadong
authors: J
authors: Fan
authors: Wei
authors: W
authors: Hong
authors: Lianyun
authors: L
authors: Li
authors: Min
authors: M
authors: Wu
keywords: Cancer; Cell cycle; DNA damage response; DNA methylation; FCdR; p53
references: J Mol Biol. 2003 Jun 13;329(4):675-84
references: 12787669
references: Nature. 2012 Jan 18;481(7381):287-94
references: 22258607
references: N Engl J Med. 2008 Mar 13;358(11):1148-59
references: 18337604
references: J Thorac Oncol. 2008 Apr;3(4):417-21
references: 18379362
references: Cell. 2009 May 1;137(3):413-31
references: 19410540
references: Cell Signal. 2011 Jul;23(7):1082-93
references: 21345368
references: Cell. 2001 Feb 9;104(3):329-32
references: 11239390
references: Trends Cell Biol. 2010 May;20(5):299-309
references: 20172729
references: Cell. 1980 May;20(1):85-93
references: 6156004
references: Cell Death Differ. 2006 Jun;13(6):1017-26
references: 16557268
references: Curr Opin Genet Dev. 2011 Feb;21(1):86-92
references: 21317061
references: Cell. 2009 May 15;137(4):609-22
references: 19450511
references: Drug Discov Today. 2011 Aug;16(15-16):683-90
references: 21601651
references: Nat Rev Genet. 2005 Aug;6(8):597-610
references: 16136652
references: Nat Rev Cancer. 2008 Dec;8(12):957-67
references: 19005492
references: Nat Rev Mol Cell Biol. 2000 Dec;1(3):179-86
references: 11252893
references: Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27
references: 18594563
references: Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8
references: 17899082
references: Cancer Biol Ther. 2004 Nov;3(11):1062-8
references: 15539938
references: Mol Cancer Ther. 2009 Jun;8(6):1409-20
references: 19509247
references: Trends Cell Biol. 2010 Jan;20(1):14-24
references: 19879762
references: Clin Cancer Res. 2006 Dec 15;12(24):7483-91
references: 17138702
references: Mol Cancer Ther. 2005 Oct;4(10):1515-20
references: 16227400